Skip to main content
Top
Published in: Diabetologia 11/2016

01-11-2016 | Article

Soluble CD163, adiponectin, C-reactive protein and progression of dysglycaemia in individuals at high risk of type 2 diabetes mellitus: the ADDITION-PRO cohort

Authors: Pia Deichgræber, Daniel R. Witte, Holger J. Møller, Mette V. Skriver, Bjørn Richelsen, Marit E. Jørgensen, Nanna B. Johansen, Annelli Sandbæk

Published in: Diabetologia | Issue 11/2016

Login to get access

Abstract

Aim/hypothesis

Our aim was to investigate the association between the macrophage-activation marker soluble CD163 (sCD163), adiponectin, C-reactive protein (CRP) and changes in glycaemia, insulin resistance and insulin secretion in individuals at high risk of type 2 diabetes mellitus.

Methods

This prospective study included 1014 individuals at high risk of type 2 diabetes mellitus participating in the Danish arm of the Anglo-Danish-Dutch study of Intensive Treatment In PeOple with ScreeN-detected Diabetes in Primary Care (ADDITION-Europe trial) baseline examination in 2001–2006 and follow-up examination (ADDITION-Progression [ADDITION-PRO]) in 2009–2011. Baseline serum samples were analysed for sCD163, adiponectin and CRP. The associations between sCD163, adiponectin and CRP per doubling of concentration, and changes per year in HbA1c, fasting plasma glucose, 2 h glucose, fasting insulin, HOMA-IR and HOMA-β were assessed using a mixed-effects model.

Results

A doubling of sCD163 concentration was positively associated with changes in HOMA-β (β = 1.160 per year, 95% CI 0.345, 1.975) as well as a doubling of CRP concentration (β = 0.410 per year, 95% CI 0.051, 0.769) after adjustment for age and sex. A doubling of adiponectin was inversely associated with changes in 2 h glucose (β =−0.063 per year, 95% CI −0.111, −0.014), HOMA-IR (β =−0.038 per year, 95% CI −0.060, −0.015) and HOMA-β (β =−1.028 per year, 95% CI −1.635, −0.421) after adjustment for age and sex. The associations were robust to adjustment for baseline waist circumference and smoking. Adjustment for CRP did not change the associations for sCD163 or adiponectin.

Conclusions/interpretation

Our findings indicate that mechanisms related to inflammation, including macrophage activation and adipocyte metabolism, may play a role in changes in glucose homeostasis in individuals at high risk of type 2 diabetes mellitus.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pickup JC, Crook MA (1998) Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41:1241–1248CrossRefPubMed Pickup JC, Crook MA (1998) Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41:1241–1248CrossRefPubMed
2.
go back to reference Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N (2014) Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract 105:141–150CrossRefPubMed Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N (2014) Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract 105:141–150CrossRefPubMed
3.
4.
go back to reference Moller HJ, Peterslund NA, Graversen JH, Moestrup SK (2002) Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood 99:378–380CrossRefPubMed Moller HJ, Peterslund NA, Graversen JH, Moestrup SK (2002) Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood 99:378–380CrossRefPubMed
5.
go back to reference Weaver LK, Hintz-Goldstein KA, Pioli PA et al (2006) Pivotal advance: activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163. J Leukoc Biol 80:26–35CrossRefPubMed Weaver LK, Hintz-Goldstein KA, Pioli PA et al (2006) Pivotal advance: activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163. J Leukoc Biol 80:26–35CrossRefPubMed
7.
go back to reference Parkner T, Sorensen LP, Nielsen AR et al (2012) Soluble CD163: a biomarker linking macrophages and insulin resistance. Diabetologia 55:1856–1862CrossRefPubMed Parkner T, Sorensen LP, Nielsen AR et al (2012) Soluble CD163: a biomarker linking macrophages and insulin resistance. Diabetologia 55:1856–1862CrossRefPubMed
8.
go back to reference Rojo-Martinez G, Maymo-Masip E, Rodriguez MM et al (2014) Serum sCD163 levels are associated with type 2 diabetes mellitus and are influenced by coffee and wine consumption: results of the Di@bet.es study. PLoS One 9:e101250CrossRefPubMedCentralPubMed Rojo-Martinez G, Maymo-Masip E, Rodriguez MM et al (2014) Serum sCD163 levels are associated with type 2 diabetes mellitus and are influenced by coffee and wine consumption: results of the Di@bet.es study. PLoS One 9:e101250CrossRefPubMedCentralPubMed
9.
go back to reference Zanni MV, Burdo TH, Makimura H, Williams KC, Grinspoon SK (2011) Relationship between monocyte/macrophage activation marker soluble CD163 and insulin resistance in obese and normal-weight subjects. Clin Endocrinol (Oxf) 77:385–390CrossRef Zanni MV, Burdo TH, Makimura H, Williams KC, Grinspoon SK (2011) Relationship between monocyte/macrophage activation marker soluble CD163 and insulin resistance in obese and normal-weight subjects. Clin Endocrinol (Oxf) 77:385–390CrossRef
10.
go back to reference Moller HJ, Frikke-Schmidt R, Moestrup SK, Nordestgaard BG, Tybjaerg-Hansen A (2011) Serum soluble CD163 predicts risk of type 2 diabetes in the general population. Clin Chem 57:291–297CrossRefPubMed Moller HJ, Frikke-Schmidt R, Moestrup SK, Nordestgaard BG, Tybjaerg-Hansen A (2011) Serum soluble CD163 predicts risk of type 2 diabetes in the general population. Clin Chem 57:291–297CrossRefPubMed
13.
14.
go back to reference Sandbaek A, Griffin SJ, Rutten G et al (2008) Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. Diabetologia 51:1127–1134CrossRefPubMedCentralPubMed Sandbaek A, Griffin SJ, Rutten G et al (2008) Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. Diabetologia 51:1127–1134CrossRefPubMedCentralPubMed
15.
go back to reference Johansen NB, Hansen AL, Jensen TM et al (2012) Protocol for ADDITION-PRO: a longitudinal cohort study of the cardiovascular experience of individuals at high risk for diabetes recruited from Danish primary care. BMC Public Health 12:1078CrossRefPubMedCentralPubMed Johansen NB, Hansen AL, Jensen TM et al (2012) Protocol for ADDITION-PRO: a longitudinal cohort study of the cardiovascular experience of individuals at high risk for diabetes recruited from Danish primary care. BMC Public Health 12:1078CrossRefPubMedCentralPubMed
16.
go back to reference D’Orazio P, Burnett RW, Fogh-Andersen N et al (2005) Approved IFCC recommendation on reporting results for blood glucose (abbreviated). Clin Chem 51:1573–1576CrossRefPubMed D’Orazio P, Burnett RW, Fogh-Andersen N et al (2005) Approved IFCC recommendation on reporting results for blood glucose (abbreviated). Clin Chem 51:1573–1576CrossRefPubMed
17.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed
18.
go back to reference Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27:1487–1495CrossRefPubMed Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27:1487–1495CrossRefPubMed
19.
go back to reference Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimaki M, Witte DR (2009) Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373:2215–2221CrossRefPubMedCentralPubMed Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimaki M, Witte DR (2009) Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373:2215–2221CrossRefPubMedCentralPubMed
20.
go back to reference Fjeldborg K, Christiansen T, Bennetzen M, J Moller H, Pedersen SB, Richelsen B (2013) The macrophage-specific serum marker, soluble CD163, is increased in obesity and reduced after dietary-induced weight loss. Obesity (Silver Spring) 21:2437–2443CrossRef Fjeldborg K, Christiansen T, Bennetzen M, J Moller H, Pedersen SB, Richelsen B (2013) The macrophage-specific serum marker, soluble CD163, is increased in obesity and reduced after dietary-induced weight loss. Obesity (Silver Spring) 21:2437–2443CrossRef
21.
go back to reference Thamer C, Haap M, Heller E et al (2006) Beta cell function, insulin resistance and plasma adiponectin concentrations are predictors for the change of postprandial glucose in non-diabetic subjects at risk for type 2 diabetes. Horm Metab Res 38:178–182CrossRefPubMed Thamer C, Haap M, Heller E et al (2006) Beta cell function, insulin resistance and plasma adiponectin concentrations are predictors for the change of postprandial glucose in non-diabetic subjects at risk for type 2 diabetes. Horm Metab Res 38:178–182CrossRefPubMed
22.
go back to reference Bennett NR, Boyne MS, Cooper RS et al (2009) Impact of adiponectin and ghrelin on incident glucose intolerance and on weight change. Clin Endocrinol (Oxf) 70:408–414CrossRef Bennett NR, Boyne MS, Cooper RS et al (2009) Impact of adiponectin and ghrelin on incident glucose intolerance and on weight change. Clin Endocrinol (Oxf) 70:408–414CrossRef
23.
go back to reference Yamamoto Y, Hirose H, Saito I, Nishikai K, Saruta T (2004) Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J Clin Endocrinol Metab 89:87–90CrossRefPubMed Yamamoto Y, Hirose H, Saito I, Nishikai K, Saruta T (2004) Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J Clin Endocrinol Metab 89:87–90CrossRefPubMed
24.
go back to reference Kluppelholz B, Thorand B, Koenig W et al (2015) Association of subclinical inflammation with deterioration of glycaemia before the diagnosis of type 2 diabetes: the KORA S4/F4 study. Diabetologia 58:2269–2277CrossRefPubMed Kluppelholz B, Thorand B, Koenig W et al (2015) Association of subclinical inflammation with deterioration of glycaemia before the diagnosis of type 2 diabetes: the KORA S4/F4 study. Diabetologia 58:2269–2277CrossRefPubMed
25.
go back to reference Tabak AG, Brunner EJ, Miller MA et al (2009) Low serum adiponectin predicts 10-year risk of type 2 diabetes and HbA1c independently of obesity, lipids, and inflammation: Whitehall II study. Horm Metab Res 41:626–629CrossRefPubMedCentralPubMed Tabak AG, Brunner EJ, Miller MA et al (2009) Low serum adiponectin predicts 10-year risk of type 2 diabetes and HbA1c independently of obesity, lipids, and inflammation: Whitehall II study. Horm Metab Res 41:626–629CrossRefPubMedCentralPubMed
26.
go back to reference Park K, Steffes M, Lee DH, Himes JH, Jacobs DR Jr (2009) Association of inflammation with worsening HOMA-insulin resistance. Diabetologia 52:2337–2344CrossRefPubMedCentralPubMed Park K, Steffes M, Lee DH, Himes JH, Jacobs DR Jr (2009) Association of inflammation with worsening HOMA-insulin resistance. Diabetologia 52:2337–2344CrossRefPubMedCentralPubMed
27.
go back to reference Tabak AG, Kivimaki M, Brunner EJ et al (2010) Changes in C-reactive protein levels before type 2 diabetes and cardiovascular death: the Whitehall II study. Eur J Endocrinol 163:89–95CrossRefPubMed Tabak AG, Kivimaki M, Brunner EJ et al (2010) Changes in C-reactive protein levels before type 2 diabetes and cardiovascular death: the Whitehall II study. Eur J Endocrinol 163:89–95CrossRefPubMed
28.
go back to reference Carstensen B, Lindstrom J, Sundvall J, Borch-Johnsen K, Tuomilehto J, DPS Study Group (2008) Measurement of blood glucose: comparison between different types of specimens. Ann Clin Biochem 45:140–148CrossRefPubMed Carstensen B, Lindstrom J, Sundvall J, Borch-Johnsen K, Tuomilehto J, DPS Study Group (2008) Measurement of blood glucose: comparison between different types of specimens. Ann Clin Biochem 45:140–148CrossRefPubMed
29.
go back to reference Kuwa K, Nakayama T, Hoshino T, Tominaga M (2001) Relationships of glucose concentrations in capillary whole blood, venous whole blood and venous plasma. Clin Chim Acta 307:187–192CrossRefPubMed Kuwa K, Nakayama T, Hoshino T, Tominaga M (2001) Relationships of glucose concentrations in capillary whole blood, venous whole blood and venous plasma. Clin Chim Acta 307:187–192CrossRefPubMed
30.
go back to reference Kruijshoop M, Feskens EJ, Blaak EE, de Bruin TW (2004) Validation of capillary glucose measurements to detect glucose intolerance or type 2 diabetes mellitus in the general population. Clin Chim Acta 341:33–40CrossRefPubMed Kruijshoop M, Feskens EJ, Blaak EE, de Bruin TW (2004) Validation of capillary glucose measurements to detect glucose intolerance or type 2 diabetes mellitus in the general population. Clin Chim Acta 341:33–40CrossRefPubMed
31.
go back to reference Manley SE, Stratton IM, Clark PM, Luzio SD (2007) Comparison of 11 human insulin assays: implications for clinical investigation and research. Clin Chem 53:922–932CrossRefPubMed Manley SE, Stratton IM, Clark PM, Luzio SD (2007) Comparison of 11 human insulin assays: implications for clinical investigation and research. Clin Chem 53:922–932CrossRefPubMed
32.
go back to reference Gao H, Fall T, van Dam RM et al (2013) Evidence of a causal relationship between adiponectin levels and insulin sensitivity: a Mendelian randomization study. Diabetes 62:1338–1344CrossRefPubMedCentralPubMed Gao H, Fall T, van Dam RM et al (2013) Evidence of a causal relationship between adiponectin levels and insulin sensitivity: a Mendelian randomization study. Diabetes 62:1338–1344CrossRefPubMedCentralPubMed
33.
go back to reference Yaghootkar H, Lamina C, Scott RA et al (2013) Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes. Diabetes 62:3589–3598CrossRefPubMedCentralPubMed Yaghootkar H, Lamina C, Scott RA et al (2013) Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes. Diabetes 62:3589–3598CrossRefPubMedCentralPubMed
34.
go back to reference Brunner EJ, Kivimaki M, Witte DR et al (2008) Inflammation, insulin resistance, and diabetes—Mendelian randomization using CRP haplotypes points upstream. PLoS Med 5, e155CrossRefPubMedCentralPubMed Brunner EJ, Kivimaki M, Witte DR et al (2008) Inflammation, insulin resistance, and diabetes—Mendelian randomization using CRP haplotypes points upstream. PLoS Med 5, e155CrossRefPubMedCentralPubMed
Metadata
Title
Soluble CD163, adiponectin, C-reactive protein and progression of dysglycaemia in individuals at high risk of type 2 diabetes mellitus: the ADDITION-PRO cohort
Authors
Pia Deichgræber
Daniel R. Witte
Holger J. Møller
Mette V. Skriver
Bjørn Richelsen
Marit E. Jørgensen
Nanna B. Johansen
Annelli Sandbæk
Publication date
01-11-2016
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 11/2016
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-016-4075-4

Other articles of this Issue 11/2016

Diabetologia 11/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.